Tumor Responses with Crizotinib in MET-Amplified Disease Help Define a New Targetable Form of Lung Cancer
June 2, 2014 · Comments Off
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
AURORA, Colo -The Journal of Clinical Oncology reports the case of a woman diagnosed with...
CU docs work to boost minorities in (and leading) cancer trials
April 17, 2014 · Comments Off
Focus on training minority investigators By Todd Neff Clinical trials of cancer therapies are most...
CU Cancer Center study shows that patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease. Eliminating these pockets of resistant disease allows patients to continue treating the overall condition with crizotinib, leading to improved 2-year survival rate compared with patients forced to discontinue the drug sooner.
Layers of Support
December 2, 2013 · Comments Off
Palliative care consult service helps families tailor care to meet personal desires. Barb Cassou was...
New Crizotinib Side-Effect: Reduced Measures of Kidney Function During Treatment (Recovery After)
November 20, 2013 · Comments Off
A University of Colorado Cancer Center study published today in the journal Cancer shows that using crizotinib to treat ALK positive non-small cell lung cancer (NSCLC) appears to reduce kidney function when assessed by one of the most commonly used clinical methods.
Study: Redefining the criteria for ALK positive lung cancer
September 10, 2013 · Comments Off
A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug.
Reality TV meets reality for lung cancer treatment
June 6, 2013 · Comments Off
By Todd Neff It was Memorial Day Weekend 2012, and Ross Camidge, MD, PhD, was...
Multicenter international study confirms low testosterone in 84 percent of lung cancer patients taking crizotinib
April 17, 2013 · Comments Off
Ross Camidge, MD, PhD, and international colleagues confirm low testosterone in a majority of lung cancer patients treated with crizotinib.
NTRK1: a new oncogene and target in lung cancer
April 17, 2013
amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno ASCO biomarkers bladder cancer breast cancer cancer cancer clinical trials cancer grants cancer research colorado cancer stem cells Cancer Survivorship clinical trial colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant head-and-neck cancer james degregori jennifer richer leukemia lung cancer lung cancer research melanoma ovarian cancer Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge skin cancer Thomas Flaig tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith
"I’m hoping to be able to breathe better and live a little bit longer to be a mom to my baby girl." Tabitha... fb.me/2feb9fMGv
A mother’s love for her children is like nothing else. Tabitha is a non-smoker with Stage IV lung cancer who is... fb.me/6AVJIIUIx
Our Cancer Center is now ranked #15 In the US News and World Report ranking for cancer! A nice steady climb the... fb.me/1pOzjxyEH
We all enjoy bringing our friends and family meals when they're sick. It helps ease their burdens and gives them... fb.me/35IusLDcl
"It’s known best as a long-term treatment for breast-cancer survivors. But it’s also a preventive therapy:... fb.me/3D1WR8ivA